Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success ...

One of the highlights of Eli Lilly's third-quarter results was ... with fewer than 10% switching from Trulicity, said Lilly's chief financial officer Anat Ashkenazi on the call.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.